Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ColiFin in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection (DZL-Eradicate)
2023-509277-22-00Phase 2Authorised
- Sponsor
- Philipps-Universität Marburg
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of colistimethate sodium in bronchiectasis and Pseudomonas aeruginosa airway infection (2 arms), sponsored by Philipps-Universität Marburg. Primary endpoint: Proportion of sputum/airway culture negativity for PA at 28 weeks. Planned start Jun 2022; status: authorised.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasisPseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on 2023-509277-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509277-22-00.